NO943388L - Selective change of antibody immunogenicity - Google Patents
Selective change of antibody immunogenicityInfo
- Publication number
- NO943388L NO943388L NO943388A NO943388A NO943388L NO 943388 L NO943388 L NO 943388L NO 943388 A NO943388 A NO 943388A NO 943388 A NO943388 A NO 943388A NO 943388 L NO943388 L NO 943388L
- Authority
- NO
- Norway
- Prior art keywords
- idiotype
- immunogenicity
- response
- antibody
- selective change
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Den foreliggende oppfinnelsen vedrører en enkel frem- gangsmåte for modifikasjon av f.eks. anti-TAA antistoffer som forandrer deres immunogenisitet slik at deres evne til å indusere en anti-isotyp respons selektivt reduseres, mens de forblir istand til å utløse en anti-idiotyp respons. Det sistnevnte er av potensiell immunoterapeutisk verdi, dvs. ved aktivering av idiotyp-anti-idiotyp nettverket. Denne modifikasjonen dannes som en kontrollert og delvis reduksjon av antistoffet, og effektorområder er bevart. Oppfinnelsen bør tillate gjentatte injeksjoner (for diagnose og terapi) og redusere HAMA interferens i serodiagnostiske målinger.The present invention relates to a simple method of modifying e.g. anti-TAA antibodies that alter their immunogenicity so as to selectively reduce their ability to induce an anti-isotype response, while remaining capable of triggering an anti-idiotype response. The latter is of potential immunotherapeutic value, i.e., by activating the idiotype-anti-idiotype network. This modification is formed as a controlled and partial reduction of the antibody, and effector regions are conserved. The invention should allow repeated injections (for diagnosis and therapy) and reduce HAMA interference in serodiagnostic measurements.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85360592A | 1992-03-18 | 1992-03-18 | |
PCT/CA1993/000110 WO1993018792A1 (en) | 1992-03-18 | 1993-03-18 | Selective alteration of antibody immunogenicity |
Publications (2)
Publication Number | Publication Date |
---|---|
NO943388D0 NO943388D0 (en) | 1994-09-12 |
NO943388L true NO943388L (en) | 1994-11-18 |
Family
ID=25316485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO943388A NO943388L (en) | 1992-03-18 | 1994-09-12 | Selective change of antibody immunogenicity |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0631507A1 (en) |
JP (1) | JPH07504668A (en) |
AU (1) | AU3881593A (en) |
CA (1) | CA2131621A1 (en) |
FI (1) | FI944314A (en) |
NO (1) | NO943388L (en) |
WO (1) | WO1993018792A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121041A0 (en) | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
JP2002504154A (en) * | 1997-06-17 | 2002-02-05 | アルタレックス コーポレイション | Therapeutic compositions and methods of treatment |
US8796425B2 (en) | 2009-12-23 | 2014-08-05 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4661586A (en) * | 1981-11-17 | 1987-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
US4816249A (en) * | 1981-11-17 | 1989-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
-
1993
- 1993-03-18 CA CA 2131621 patent/CA2131621A1/en not_active Abandoned
- 1993-03-18 EP EP93907685A patent/EP0631507A1/en not_active Withdrawn
- 1993-03-18 AU AU38815/93A patent/AU3881593A/en not_active Abandoned
- 1993-03-18 JP JP5516130A patent/JPH07504668A/en active Pending
- 1993-03-18 WO PCT/CA1993/000110 patent/WO1993018792A1/en not_active Application Discontinuation
-
1994
- 1994-09-12 NO NO943388A patent/NO943388L/en unknown
- 1994-09-16 FI FI944314A patent/FI944314A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO943388D0 (en) | 1994-09-12 |
AU3881593A (en) | 1993-10-21 |
EP0631507A1 (en) | 1995-01-04 |
FI944314A0 (en) | 1994-09-16 |
CA2131621A1 (en) | 1993-09-30 |
WO1993018792A1 (en) | 1993-09-30 |
FI944314A (en) | 1994-09-16 |
JPH07504668A (en) | 1995-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI934861A0 (en) | Foerfarande Foer framstaellning av 3a-hydroxi, 3b-substituerade pregnaner | |
NO20004946L (en) | Humanized antibody to human tissue factor (TF) and method of producing the humanized antibody | |
DE69433663D1 (en) | ANTIBODIES AGAINST HUMAN PROSTATE-SPECIFIC GALLIC CALLIC REIN | |
EP0675904A4 (en) | Human neutralizing monoclonal antibodies to human immunodeficiency virus. | |
TR199901174T2 (en) | New heterocyclylmethyl-substituted pyrazole derivatives. | |
ATE377027T1 (en) | TETRAVALENT ANTIBODIES CONSTRUCTS | |
DK517380A (en) | HYBRID CELL LINE AND PROCEDURES FOR PRODUCING AND USING THEREOF | |
ES2136760T3 (en) | PRODUCTION OF HUMANIZED IMMUNOGLOBULINS AND CORRESPONDING POLYNUCLEOTIDES. | |
HUP0301235A2 (en) | Treatment of central nervous system diseases by antibodies against glatiramer acetate | |
NO943388L (en) | Selective change of antibody immunogenicity | |
SE7807950L (en) | PROCEDURE FOR THE PREPARATION OF POROS, PURE SILICO DIOXIDE | |
BR9708843B1 (en) | Diagnostic methods of control loop malfunction. | |
MX9305920A (en) | RECONFIGURED MONOCLONAL ANTIBODIES, AGAINST AN IMMUNOGLOBULIN ISOTYPE. | |
KR900009595A (en) | Method for producing 2-chloro-5-chloromethylpyridine | |
SE425322B (en) | PROCEDURE FOR THE PREPARATION OF ALKALIMETAL OR EARTHALKALIMETAL CHLORITE | |
DE69434796D1 (en) | CHLAMYDIA VACCINE CONTAINING ANTI-IDIOTYPIC ANTIBODIES | |
ATE361980T1 (en) | POLYPEPTIDE FRAGMENTS ABLE TO COMPETE WITH THE ANTIGEN I/II OF STREPTOCOCCUS MUTANS | |
NO952157D0 (en) | Method of producing tear-off cap, as well as tear-off cap made by this method | |
ATE144286T1 (en) | MONOCLONAL ANTIBODIES AGAINST THE PLASMIN-ANTIPLASMIN COMPLEX, METHOD FOR THEIR PRODUCTION AND THEIR USE | |
SE7800990L (en) | PROCEDURE FOR THE PREPARATION OF 5- (2-CHLOROBENZYL) -4,5,6,7-TETRAHYDROTIENO (3,2-C) PYRIDINE | |
ATE283282T1 (en) | EPITOPES OF THE SHIGELLA-LIKE TOXIN AND THEIR USE AS A VACCINE AND IN DIAGNOSTICS | |
JPS5450513A (en) | Liquid shampoo composition | |
JPS52139886A (en) | Sequence controller | |
JPS53108335A (en) | Microprogram control type information processor | |
JPS53108328A (en) | Microprogram control type information processor |